昭衍新药拟3月30日举行董事会会议审批年度业绩

Group 1 - The company, Zhaoyan New Drug (06127.HK), announced a board meeting scheduled for March 30, 2026, to consider and approve the annual performance for the year ending December 31, 2025 [1] - The board will also discuss the proposal for a final dividend distribution, if applicable, along with other matters [1]